Immunovant financials
$33.46−0.09%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '26 Mar 31 | Q3 '26 Dec 31 | Q2 '26 Sep 30 | Q1 '26 Jun 30 | Q4 '25 Mar 31 | Q3 '25 Dec 31 | Q2 '25 Sep 30 | Q1 '25 Jun 30 | Q4 '24 Mar 31 | Q3 '24 Dec 31 | Q2 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$160.3M | -$159.6M | -$114.4M | -$131.8M | -$127.2M | -$113.8M | -$114.3M | -$115.7M | -$94.3M | -$80.9M | -$61.6M | -$61.8M |
| Net income | -$153.2M | -$147.9M | -$110.6M | -$126.5M | -$120.6M | -$106.4M | -$111.1M | -$109.1M | -$87.2M | -$75.3M | -$51.4M | -$58.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.75 | $-0.73 | $-0.61 | $-0.73 | $-0.71 | $-0.64 | $-0.76 | $-0.74 | $-0.60 | $-0.52 | $-0.36 | $-0.45 |
| EBITDA | -$160.2M | -$159.5M | -$114.3M | -$131.7M | -$127.1M | -$113.7M | -$114.2M | -$115.7M | -$94.2M | -$93.4M | -$61.5M | -$61.7M |
| Operating cash flow | -$124.4M | -$95.1M | -$92.3M | -$102.5M | -$117.4M | -$110.6M | -$100.4M | -$88.6M | -$76.2M | -$59.7M | -$47.1M | -$60.1M |
| Free cash flow | -$124.4M | -$95.1M | -$92.3M | -$102.5M | -$117.4M | -$110.8M | -$100.6M | -$88.8M | -$76.4M | -$59.8M | -$47.2M | -$60.1M |
| Diluted shares | 205.5M | 203.7M | 181.5M | 173.6M | 170.9M | 166.8M | 146.9M | 146.5M | 146.1M | 146.2M | 144.5M | 131.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $797.8M | $902.1M | $994.5M | $521.9M | $598.9M | $714.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $852.5M | $957.0M | $1.05B | $583.0M | $661.4M | $776.2M |
| Total liabilities | $117.1M | $104.4M | $66.3M | $63.3M | $52.9M | $68.8M |
| Shareholders' equity | $735.4M | $852.6M | $986.1M | $519.7M | $608.5M | $707.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology